Navigation Links
Updated Phase 1 Data for Exelixis' XL184 Demonstrate Pharmacodynamic and Clinical Anti-Tumor Activity
Date:10/23/2007

-Encouraging signs of anti-tumor activity observed in patients with

medullary thyroid cancer-

SAN FRANCISCO, Oct. 23 /PRNewswire-FirstCall/ -- Exelixis, Inc. (Nasdaq: EXEL) today reported encouraging data from an ongoing phase 1 trial of XL184, a potent inhibitor of MET, RET, and VEGFR kinases, in patients with advanced solid tumors or lymphoma. Anti-tumor activity has been observed in a variety of cancers at doses that are not associated with significant toxicity. Consistent with the anti-VEGFR activity of XL184, preliminary pharmacodynamic analyses show reductions in several biomarkers of angiogenesis. Data were presented today in a poster session (Abstract #A152) at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics, which is being held October 22-26, 2007 in San Francisco.

There were 33 patients available for safety, pharmacokinetic, and tumor response analyses as of the June 22, 2007 cutoff; further data were also provided for six additional patients after the cutoff. Of seven patients with medullary thyroid cancer (MTC), three have had partial responses (2 confirmed and 1 unconfirmed). Six of the seven patients had tumor shrinkage and one had non-measurable disease. All seven assessable patients with MTC experienced a rapid decrease in plasma levels of calcitonin, a marker frequently elevated in medullary thyroid cancer, and six of the seven patients had a decrease in the tumor marker carcinoembryonic antigen (CEA). All seven MTC patients are still on study. In addition, one patient with a neuroendocrine tumor has an unconfirmed partial response. In total, 15 patients with various solid malignancies or lymphoma have had stable disease
'/>"/>

SOURCE Exelixis, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Infinity and MedImmune Present Updated Phase I Results of IPI-504 in GIST at ASCO Annual Meeting
2. Updated Study Results Reinforce Survival Benefit of Taxotere (Docetaxel) for Men with Advanced, Hormone-Resistant Prostate Cancer
3. Introgen Reports Updated Phase 2 Advexin Data Correlating Improved Survival, Tumor Responses and Predictive p53 Biomarker
4. Updated Overall Survival Data From Pivotal Herceptin Adjuvant Studies in HER2-Positive Breast Cancer
5. Vion Pharmaceuticals Presents Updated Clinical Data from a Phase II trial of Cloretazine (VNP40101M) in Patients with Relapsed or Refractory Small Cell Lung Cancer
6. Infinity and MedImmune Announce Updated Data On Ipi-504 to be Presented At ASCO
7. Avanir Pharmaceuticals Presents IEED Prevalence and Updated Zenvia Long-Term Safety Data at AAN Annual Meeting
8. Media Advisory: ACC Updated Schedule
9. Data Available From Erbitux Phase III Study in First-Line Treatment of Advanced Lung Cancer
10. Phase 3 Results for Dabigatran Etexilate, an Investigational Oral Anticoagulant, Presented Today at the XXIst Congress of the International Society on Thrombosis and Haemostasis
11. YM BioSciences Announces Secondary Efficacy and Safety Findings in Randomized Phase IIB Aerolef Trial
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/24/2014)... , Dec. 23, 2014 Echo ... medical device company focused on skin permeation, continuous ... Scott W. Hollander has been appointed ... Hollander has more than 20 years of experience ... industries, and most recently served as Vice President, ...
(Date:12/24/2014)... DALLAS , December 24, 2014 /PRNewswire/ ... Research Report on Global Disposable Syringe Industry ... to its online business intelligence library. ... Global Disposable Syringe Industry is a professional ... Syringe market.  For overview analysis, the report ...
(Date:12/24/2014)... 23, 2014  Lockton Dunning Benefits, the ... announced the addition of Vice President Kim ... Dunning,s Pharmacy Consulting team, Excelsior Solutions. ... experience to the position.  Most recently, she worked ... Diplomat Specialty Pharmacy, where she has held various ...
Breaking Medicine Technology:Echo Therapeutics Announces Scott W. Hollander as President & Chief Executive Officer 2Echo Therapeutics Announces Scott W. Hollander as President & Chief Executive Officer 3World Disposable Syringe Market 2014 Report: China and Regional Analysis 2World Disposable Syringe Market 2014 Report: China and Regional Analysis 3World Disposable Syringe Market 2014 Report: China and Regional Analysis 4World Disposable Syringe Market 2014 Report: China and Regional Analysis 5Kim Foerster Joins Lockton Companies 2
... Cempra Pharmaceuticals Inc. today announced that Prabhavathi Fernandes, ... Capital Markets 6th Annual Healthcare Conference on November 17, 2009 ... New York City. Dr. Fernandes will provide an overview ... treatment of drug-resistant pathogens including MRSA. , About Cempra ...
... Nov. 13 Warner Chilcott plc (Nasdaq: WCRX ... its ordinary shares by certain selling shareholders. The ... DLJ Merchant Banking, J.P. Morgan Partners (advised by CCMP ... institutional investors and members of the Company,s senior management. ...
Cached Medicine Technology:Warner Chilcott Announces Secondary Equity Offering 2Warner Chilcott Announces Secondary Equity Offering 3Warner Chilcott Announces Secondary Equity Offering 4
(Date:12/25/2014)... Recently, iFitDress.com, the popular online supplier of wedding dresses and ... of black one-shoulder cocktail dresses . In addition, all ... at discounted prices, up to 70% off. , ... weeks only. You know, we have thousands of frequent callers ... new items can visit our website for more details. The ...
(Date:12/25/2014)... BambooFlooringChina.com sells many bamboo products and the business ... company announces big discounts on its bamboo mats ... BambooFlooringChina.com is the world’s leader in bamboo flooring. According ... Jan. 20, 2015. , The bamboo mats are made ... thread. All the bamboo strips for the mats are ...
(Date:12/25/2014)... Dennis Thompson HealthDay ... Very sick children with complex chronic illnesses can receive effective, ... "medical home," with easy access to a team of dedicated ... less likely to become seriously ill and need either hospitalization ... treatment at an enhanced medical home clinic at the University ...
(Date:12/25/2014)... HealthDay Reporter WEDNESDAY, Dec. 24, ... a "fountain of youth" drug that can delay the effects ... new study suggests. Seniors received a significant boost to ... genetic signaling pathway linked to aging and immune function, researchers ... experimental medication, a version of the drug rapamycin, improved the ...
(Date:12/25/2014)... 25, 2014 Plugin creators from Pixel ... A fully customizable business presentation tool made specifically for ... ProFire 5k business tool, users can now display their ... of Pixel Film Studios. “ProFire 5k gives users a ... add professionalism to a presentation” , Pixel Film Studios ...
Breaking Medicine News(10 mins):Health News:iFitDress.com: Black One-Shoulder Cocktail Dresses for 2015 2Health News:Various Styles of Bamboo Mats in Many Colors from BambooFlooringChina.com 2Health News:Coordinated Care Through 'Medical Home' Best for Chronically Ill Kids: Study 2Health News:Coordinated Care Through 'Medical Home' Best for Chronically Ill Kids: Study 3Health News:Researchers Take 'First Baby Step' Toward Anti-Aging Drug 2Health News:Researchers Take 'First Baby Step' Toward Anti-Aging Drug 3Health News:Announcing a new ProFire 5k plugin from Pixel Film Studios for Final Cut Pro X Professionals 2
... study published in the journal Acta Obstetricia et ... (body mass index, BMI) and weight gain in pregnancy ... since high birthweight may also predict adult overweight. ... Department of Pediatrics at Soerlandet Hospital and the University ...
... A large-scale analysis of patients whose myelodysplastic syndrome is ... all of them have a poor prognosis, researchers from ... at the 53rd Annual Meeting of the American Society ... earlier radiation, chemotherapy or both treatments are usually told ...
... apricot - telling these smells apart is no problem for ... smells has been uncovered by an interdisciplinary team of researchers ... light on the dynamics of the three-dimensional structure of the ... also found a characteristic pattern of hydrogen bonds between odorant ...
... San Diego, CA -- After the US Prostate Cancer Prevention ... prostate specific antigen (PSA), many debated which PSA level should ... Task Force (USPSTF) recently concluded, amid considerable controversy, that the ... 75 years old at all, because the risks outweigh the ...
... HealthDay Reporter , MONDAY, Dec. 12 (HealthDay News) -- ... frequently undergo an MRI beforehand. But a new study finds ... value for these patients. Researchers at Johns Hopkins University ... improve results for patients who are candidates for the injection, ...
... a new collaboration with the American College of Physicians ... to 100 practices free, one-year access to a new ... serve their patients. The tool, known as the Medical ... how IBC is working with area physicians and respected ...
Cached Medicine News:Health News:Prognostic model developed for MDS related to prior cancer therapy 2Health News:Prognostic model developed for MDS related to prior cancer therapy 3Health News:A good nose: RUB-Researchers decipher interaction of fragrances and olfactory receptors 2Health News:Biopsy referral after PSA screening stays consistent over time 2Health News:Study Questions Use of MRI Before Back-Pain Injections 2Health News:Study Questions Use of MRI Before Back-Pain Injections 3Health News:Independence Blue Cross teams with American College of Physicians to improve primary care 2
Reliable and Affordable. The Schuco 3000 Nebulizer by Allied has been designed to offer a compact style that provides worry-free affordable nebulizer therapy....
... Graham-Field has been developing diverse ... 58 years. Our medical-surgical products ... for innovation, quality and customer ... include the Labtron® line of ...
... Nebulizers deliver particulate humidity in the 3 ... secretion patients. For your convenience, Thera-Mist® nebulizers ... of sterile water., ,The P30000N, for ... 20-50% with a total flow range of ...
... Hand Held Nebulizer can be held at angles ... has a built in spill column, finger grooves ... medication setups and 7 feet of regular oxygen ... maintain small particle size and sustain optimum mist ...
Medicine Products: